{"id":"cart","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL2270409","moleculeType":"Small molecule","molecularWeight":"273.81"},"_dailymed":{"setId":"659d6669-602a-4f0d-8f86-f40650fff4a8","title":"CARTILAGE LIQUESCENCE 3020 (CARTILAGE LIQUESCENCE) LIQUID [PROFESSIONAL COMPLEMENTARY HEALTH FORMULAS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"cART (chimeric antigen receptor T-cell therapy) involves extracting T cells from a patient, genetically modifying them to express a chimeric antigen receptor that targets tumor-associated antigens, expanding these engineered cells ex vivo, and reinfusing them to attack malignant cells. This approach combines the specificity of antibody targeting with the cytotoxic power of T-cell immunity.","oneSentence":"cART is a chimeric antigen receptor T-cell therapy that engineers a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T04:30:39.316Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (specific indications depend on CAR construct and clinical development stage)"}]},"trialDetails":[{"nctId":"NCT06038474","phase":"PHASE2","title":"Descartes-08 for Patients With Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cartesian Therapeutics","startDate":"2024-02-12","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":6},{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT05674175","phase":"PHASE1, PHASE2","title":"Co-administration of CART22-65s and huCART19 for B-ALL","status":"RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2023-01-25","conditions":"B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma","enrollment":93},{"nctId":"NCT05621291","phase":"NA","title":"A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"B-All, Acute Lymphoblastic Leukemia","enrollment":60},{"nctId":"NCT07465549","phase":"NA","title":"CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-10-22","conditions":"Hypertension","enrollment":400},{"nctId":"NCT05514327","phase":"NA","title":"A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-09-01","conditions":"Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy","enrollment":20},{"nctId":"NCT07489534","phase":"PHASE2","title":"Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-09-29","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT07200089","phase":"PHASE1","title":"Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-05-31","conditions":"Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":40},{"nctId":"NCT07350863","phase":"PHASE1","title":"U69-CART-Cells For R/R T-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-25","conditions":"Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT07392372","phase":"PHASE1","title":"A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-02-09","conditions":"HIV -1 Infection","enrollment":61},{"nctId":"NCT06153251","phase":"PHASE1","title":"A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-01-23","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":187},{"nctId":"NCT07108634","phase":"","title":"Cost-effectiveness Analyses for the Prevention of Acute Kidney Injury in Patients Undergoing Cardiac Surgery in the UK","status":"WITHDRAWN","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2026-03","conditions":"Acute Kidney Injury","enrollment":""},{"nctId":"NCT07471789","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","status":"RECRUITING","sponsor":"Gyala Therapeutics","startDate":"2026-02-04","conditions":"Acute Myeloblastic Leukaemia, Leukemia, T-Cell","enrollment":33},{"nctId":"NCT06875063","phase":"PHASE1","title":"GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2026-04-30","conditions":"Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell","enrollment":45},{"nctId":"NCT07391657","phase":"PHASE3","title":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-23","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":508},{"nctId":"NCT06185751","phase":"PHASE1","title":"Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-08-22","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT07464951","phase":"PHASE1","title":"CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2026-04-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":30},{"nctId":"NCT07454148","phase":"NA","title":"CART-BP Prospective Study for Hypertension Control","status":"ACTIVE_NOT_RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-03-25","conditions":"Hypertension","enrollment":288},{"nctId":"NCT07143617","phase":"NA","title":"Exploratory Clinical Study on the Safety of STR-P004","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-09-16","conditions":"Autoimmune Diseases","enrollment":39},{"nctId":"NCT07458659","phase":"EARLY_PHASE1","title":"Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Chulalongkorn University","startDate":"2026-06-01","conditions":"Relapsed/Refractory Multiple Myeloma (MM)","enrollment":3},{"nctId":"NCT06084884","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-14","conditions":"Hepatocellular Carcinoma","enrollment":94},{"nctId":"NCT07453446","phase":"PHASE1","title":"Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma","status":"RECRUITING","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","startDate":"2025-03-04","conditions":"Relapsed or Refractory Lymphoma","enrollment":18},{"nctId":"NCT04648280","phase":"PHASE1, PHASE2","title":"Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"PENTA Foundation","startDate":"2022-06-30","conditions":"HIV Infections With Multi Drug Resistant Virus","enrollment":60},{"nctId":"NCT06066346","phase":"PHASE2","title":"A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-09-27","conditions":"Multiple Myeloma","enrollment":17},{"nctId":"NCT06947473","phase":"PHASE1, PHASE2","title":"Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2026-03-18","conditions":"Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension","enrollment":45},{"nctId":"NCT06947460","phase":"PHASE1, PHASE2","title":"CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-04-18","conditions":"Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension","enrollment":45},{"nctId":"NCT07071753","phase":"NA","title":"Optimizing Online Purchasing of Fruits, Vegetables, and Legumes for Low-Income Families","status":"NOT_YET_RECRUITING","sponsor":"New York University","startDate":"2026-07-01","conditions":"Food Insecurity, Healthy Eating","enrollment":360},{"nctId":"NCT07441525","phase":"EARLY_PHASE1","title":"UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-02-03","conditions":"Autoimmune Hemolytic Anemia, Primary Immune Thrombocytopenic Purpura, Evans Syndrome","enrollment":27},{"nctId":"NCT05870917","phase":"PHASE2","title":"A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-04-25","conditions":"Plasma Cell Leukemia","enrollment":20},{"nctId":"NCT07169500","phase":"PHASE1, PHASE2","title":"Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-03","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT06209619","phase":"PHASE1","title":"CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Nathan Denlinger","startDate":"2024-01-29","conditions":"B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent","enrollment":18},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT05041309","phase":"","title":"Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells","status":"ENROLLING_BY_INVITATION","sponsor":"Kite, A Gilead Company","startDate":"2021-12-15","conditions":"Solid and Hematological Malignancies","enrollment":1000},{"nctId":"NCT05672459","phase":"PHASE1, PHASE2","title":"A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-06-21","conditions":"Solid Tumor","enrollment":31},{"nctId":"NCT06626919","phase":"PHASE1","title":"A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases","status":"RECRUITING","sponsor":"Arcellx, Inc.","startDate":"2025-04-30","conditions":"Muscular Diseases, Neuromuscular Manifestations, Autoimmune","enrollment":30},{"nctId":"NCT03089203","phase":"PHASE1","title":"CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-03-08","conditions":"Prostate Cancer","enrollment":23},{"nctId":"NCT06267729","phase":"PHASE1, PHASE2","title":"Study of AZD0754 in Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-12","conditions":"Metastatic Prostate Cancer","enrollment":60},{"nctId":"NCT07215468","phase":"PHASE2","title":"HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study","status":"RECRUITING","sponsor":"TaiMed Biologics Inc.","startDate":"2025-12-16","conditions":"HIV -1 Infection","enrollment":75},{"nctId":"NCT07342179","phase":"NA","title":"CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2026-02-13","conditions":"Multiple Myeloma (MM)","enrollment":60},{"nctId":"NCT06236139","phase":"PHASE1, PHASE2","title":"Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-11-26","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":48},{"nctId":"NCT06801119","phase":"NA","title":"Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）","status":"RECRUITING","sponsor":"Shenzhen MagicRNA Biotechnology Co., Ltd","startDate":"2025-03-16","conditions":"Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT06965309","phase":"NA","title":"Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)","status":"TERMINATED","sponsor":"Shenzhen MagicRNA Biotechnology Co., Ltd","startDate":"2026-01-19","conditions":"Refractory Myasthenia Gravis","enrollment":9},{"nctId":"NCT03825523","phase":"NA","title":"Immediate ART in Subjects With Opportunistic Diseases","status":"COMPLETED","sponsor":"Gustavo Reyes-Teran","startDate":"2019-02-18","conditions":"HIV/AIDS, ANTIRETROVIRAL TREATMENT","enrollment":114},{"nctId":"NCT05396885","phase":"PHASE2","title":"Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-07-15","conditions":"Multiple Myeloma","enrollment":136},{"nctId":"NCT05677802","phase":"NA","title":"Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2022-12-14","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":40},{"nctId":"NCT07399769","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors","status":"RECRUITING","sponsor":"Shenzhen University General Hospital","startDate":"2024-01-01","conditions":"Advanced Solid Malignant Tumors (With Positive Expression of MSLN in Tumor Tissue)","enrollment":20},{"nctId":"NCT07234721","phase":"EARLY_PHASE1","title":"SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-01","conditions":"Relapsed and Refractory Multiple Myeloma (RRMM)","enrollment":9},{"nctId":"NCT06052956","phase":"PHASE2","title":"Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses","status":"NOT_YET_RECRUITING","sponsor":"University of Rochester","startDate":"2026-07-15","conditions":"Abscess","enrollment":120},{"nctId":"NCT06220201","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-28","conditions":"Multiple Sclerosis, Myasthenia Gravis","enrollment":120},{"nctId":"NCT04026737","phase":"","title":"Cardiovascular Effects of CART Cell Therapy","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2019-07-22","conditions":"Leukemia, Lymphoma, Cardiotoxicity","enrollment":44},{"nctId":"NCT07211737","phase":"PHASE1","title":"NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-05","conditions":"Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma","enrollment":27},{"nctId":"NCT06870526","phase":"NA","title":"Feasibility of Online-supported Delivery Bringing Optimal Nutrition to Diverse Low-income Households With Children","status":"COMPLETED","sponsor":"Cornell University","startDate":"2025-05-13","conditions":"Food Insecurity","enrollment":27},{"nctId":"NCT06549296","phase":"EARLY_PHASE1","title":"Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases","status":"SUSPENDED","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2024-09-13","conditions":"Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis","enrollment":12},{"nctId":"NCT06310811","phase":"NA","title":"Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus","status":"SUSPENDED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-03-07","conditions":"Safety, Effective","enrollment":12},{"nctId":"NCT05784415","phase":"","title":"Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2021-05-22","conditions":"Leukemia, Leukemia, Lymphoblastic, Lymphoma, Large B-Cell, Diffuse","enrollment":30},{"nctId":"NCT06775912","phase":"EARLY_PHASE1","title":"Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases","status":"RECRUITING","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2025-01-03","conditions":"SLE, Systemic Sclerosis, IIM","enrollment":18},{"nctId":"NCT07380243","phase":"NA","title":"Pathways to Prevention Food-is-Medicine Trial","status":"NOT_YET_RECRUITING","sponsor":"Amrik Singh Khalsa","startDate":"2026-02","conditions":"Heart Disease, Cardiovascular Health Status","enrollment":120},{"nctId":"NCT05127109","phase":"PHASE4","title":"The PASTDUe Nutrition Ecosystem Project (PASTDUe)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2022-04-25","conditions":"Diet, Healthy, Food, Nutrition","enrollment":300},{"nctId":"NCT04914091","phase":"","title":"Quality Of Life and Drug Use in Patients With CAR-T Cells","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-03-31","conditions":"Patients With Diffuse Large B-cell Lymphoma Treated With CART-cells","enrollment":70},{"nctId":"NCT06462144","phase":"EARLY_PHASE1","title":"IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy","status":"TERMINATED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-06-13","conditions":"Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM)","enrollment":3},{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT04800094","phase":"NA","title":"Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study","status":"COMPLETED","sponsor":"Philips Clinical & Medical Affairs Global","startDate":"2021-03-02","conditions":"Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis","enrollment":30},{"nctId":"NCT07319676","phase":"PHASE1, PHASE2","title":"Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2026-01-31","conditions":"B-cell Lymphoma Refractory","enrollment":30},{"nctId":"NCT04657523","phase":"NA","title":"Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study","status":"COMPLETED","sponsor":"Philips Clinical & Medical Affairs Global","startDate":"2020-10-30","conditions":"Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis","enrollment":60},{"nctId":"NCT06320951","phase":"PHASE2","title":"VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-12-01","conditions":"Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease","enrollment":200},{"nctId":"NCT07337785","phase":"EARLY_PHASE1","title":"CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases","status":"RECRUITING","sponsor":"Daishi Tian","startDate":"2025-12-12","conditions":"Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":36},{"nctId":"NCT05230368","phase":"PHASE1","title":"Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-12-14","conditions":"HIV-1-infection, Subtype b","enrollment":9},{"nctId":"NCT05155189","phase":"PHASE1","title":"A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2022-02-21","conditions":"Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT04627740","phase":"PHASE1, PHASE2","title":"Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2020-12-01","conditions":"Solid Tumors","enrollment":5},{"nctId":"NCT06768476","phase":"PHASE1","title":"CART123 + Ruxolitinib in Relapsed/Refractory AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-02-28","conditions":"Relapsed AML, Refractory AML","enrollment":12},{"nctId":"NCT05705869","phase":"NA","title":"Targeted Assessment in High-Risk paTients With dIAbetes to ideNtify Undiagnosed Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2022-12-22","conditions":"Heart Failure, Diabetes Mellitus, Type 1 Diabetes","enrollment":706},{"nctId":"NCT04545762","phase":"PHASE1","title":"Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"C. Babis Andreadis","startDate":"2020-09-11","conditions":"Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma","enrollment":36},{"nctId":"NCT07333430","phase":"PHASE1","title":"Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Hadassah Medical Organization","startDate":"2026-01-15","conditions":"Relapsed/Refractory Multiple Myeloma (MM)","enrollment":60},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT07309744","phase":"EARLY_PHASE1","title":"Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-12-20","conditions":"Moderate-to-severe Ulcerative Colitis, Crohn's Disease (CD)","enrollment":30},{"nctId":"NCT06361550","phase":"NA","title":"Nutritional Status Assessment and Dietary Recommendations Program (VENREDI)","status":"RECRUITING","sponsor":"University of Salamanca","startDate":"2023-11-02","conditions":"Adherence to the Mediterranean Diet","enrollment":200},{"nctId":"NCT06934382","phase":"PHASE1","title":"Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2025-04-29","conditions":"T-Cell Acute Lymphoblastic Leukemia/Lymphoma","enrollment":33},{"nctId":"NCT05098613","phase":"PHASE1","title":"Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-12-21","conditions":"Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL), Mantle Cell Lymphoma (MCL)","enrollment":68},{"nctId":"NCT04422912","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2020-09-29","conditions":"Pemphigus Vulgaris","enrollment":40},{"nctId":"NCT06456658","phase":"NA","title":"Statin Reminders for Improving Prescribing in Primary Care","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2024-08-14","conditions":"Cholesterol, Elevated, Clinical Decision Support, Education","enrollment":3332},{"nctId":"NCT06340763","phase":"","title":"JETi Hong Kong Post Market Study (PMS)","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2024-08-07","conditions":"Peripheral Venous Thrombosis, Peripheral Arterial Thrombosis, Peripheral Arteriovenous Thrombosis","enrollment":12},{"nctId":"NCT07153068","phase":"PHASE1, PHASE2","title":"SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)","enrollment":12},{"nctId":"NCT07209241","phase":"PHASE1","title":"Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-12-03","conditions":"Recurrent Glioblastoma","enrollment":12},{"nctId":"NCT02650414","phase":"PHASE1","title":"CD22 Redirected Autologous T Cells for ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2016-01-13","conditions":"B Cell Leukemias, B Cell Lymphomas","enrollment":41},{"nctId":"NCT07271121","phase":"PHASE2","title":"Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL","status":"RECRUITING","sponsor":"King Hussein Cancer Center","startDate":"2025-02-12","conditions":"Non-Hodgkin Lymphoma Refractory/ Relapsed","enrollment":26},{"nctId":"NCT03601442","phase":"","title":"CTL019 Out of Specification MAP for ALL or DLBCL Patients","status":"AVAILABLE","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":"Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":""},{"nctId":"NCT05763563","phase":"NA","title":"Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-02-21","conditions":"Lymphoma, Leukemia, Myeloma","enrollment":20},{"nctId":"NCT06056102","phase":"PHASE1","title":"CAR-T Cell Therapy for Desensitization in Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-09","conditions":"Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis","enrollment":20},{"nctId":"NCT06304636","phase":"PHASE1","title":"Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Cartesian Therapeutics","startDate":"2024-06-19","conditions":"Refractory Multiple Myeloma, Relapsed Multiple Myeloma","enrollment":4},{"nctId":"NCT07178431","phase":"PHASE1, PHASE2","title":"MB-CART2019.1 in Refractory Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Miltenyi Biomedicine GmbH","startDate":"2026-01-30","conditions":"Multiple Sclerosis, CAR T Cell Therapy","enrollment":26},{"nctId":"NCT07180992","phase":"","title":"Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-07-16","conditions":"Multiple Myeloma, Monocytes, CART Cells","enrollment":25},{"nctId":"NCT07234110","phase":"NA","title":"CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-03","conditions":"Relapsed and Refractory CD5 Hematological Tumors","enrollment":18},{"nctId":"NCT06464185","phase":"PHASE1, PHASE2","title":"A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-30","conditions":"B-cell Non-Hodgkin Lymphoma","enrollment":48},{"nctId":"NCT06420089","phase":"PHASE1","title":"CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)","status":"RECRUITING","sponsor":"Vittoria Biotherapeutics","startDate":"2024-10-04","conditions":"T Cell Non-Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT04148430","phase":"PHASE2","title":"A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-10-30","conditions":"B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma","enrollment":62},{"nctId":"NCT07219303","phase":"NA","title":"Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2025-09-25","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":80},{"nctId":"NCT02445222","phase":"PHASE3","title":"CAR-T Long Term Follow Up (LTFU) Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-02","conditions":"Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program","enrollment":1400},{"nctId":"NCT04107285","phase":"","title":"Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-09-25","conditions":"Lymphoma Receiving CAR-T Therapy","enrollment":120},{"nctId":"NCT05275998","phase":"PHASE1, PHASE2","title":"TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2022-07-05","conditions":"HIV-1-infection","enrollment":51},{"nctId":"NCT05169489","phase":"PHASE1","title":"A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-01-24","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19907,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Combination antiretroviral therapy","Antiretroviral therapy"],"phase":"marketed","status":"active","brandName":"cART","genericName":"cART","companyName":"LI Taisheng","companyId":"li-taisheng","modality":"Small molecule","firstApprovalDate":"","aiSummary":"cART is a chimeric antigen receptor T-cell therapy that engineers a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen. Used for Hematologic malignancies (specific indications depend on CAR construct and clinical development stage).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}